Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Belzutifan |
Trade Name | Welireg |
Synonyms | PT2977|MK-6482|PT-2977 |
Drug Descriptions |
Welireg (belzutifan) is a hypoxia inducible factor-2alpha (EPAS1, HIF2A) inhibitor that suppresses expression of HIF2A target genes, resulting in tumor regression (Mol Cancer Ther 2018,17(1 Suppl):Abstract nr B140, PMID: 31282155). Welireg (belzutifan) is FDA-approved for use in patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that require therapy, and in patients with advanced renal cell carcinoma who have received anti-PD-1 or PD-L1 therapy and VEGF inhibitor (FDA.gov). |
DrugClasses | HIF2A Inhibitor 6 |
CAS Registry Number | 1672668-24-4 |
NCIT ID | C135627 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Belzutifan | Abemaciclib Belzutifan | 0 | 1 |
Belzutifan | Belzutifan | 10 | 8 |
Belzutifan + Cabozantinib | Belzutifan Cabozantinib | 0 | 1 |
Belzutifan + Fulvestrant | Belzutifan Fulvestrant | 0 | 1 |
Belzutifan + HC-7366 | Belzutifan HC-7366 | 0 | 1 |
Belzutifan + Lenvatinib | Belzutifan Lenvatinib | 0 | 2 |
Belzutifan + Lenvatinib + Pembrolizumab | Belzutifan Lenvatinib Pembrolizumab | 0 | 3 |
Belzutifan + Palbociclib | Belzutifan Palbociclib | 0 | 1 |
Belzutifan + Pembrolizumab | Belzutifan Pembrolizumab | 0 | 2 |
Belzutifan + PRT1419 | Belzutifan PRT1419 | 1 | 0 |